|
|
Article: Foresight Biotherapeutics Establishes Scientific Advisory Board.
- Article from:
- Business Wire
- Article date:
- September 30, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Foresight Biotherapeutics announced today the formation of its scientific advisory board to provide guidance to the company for the development of it's lead product FST-100, a novel formulation of dexamethasone that includes povidone-iodine. Foresight's Scientific Advisory Board is comprised of leaders in the field of Ophthalmology. These highly regarded experts will advise the company on its clinical programs, regulatory strategy and provide strategic guidance to support the development of FST-100 in multiple indications.
The Scientific Advisory Board consists of the following leading Ophthalmologists:
Eduardo C. Alfonso, M.D. Dr. Alfonso is ...